Recent Updates — LAB
Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on healthcare industries. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until the deal closes, the Microfluidics unit will continue to operate as part of Standard BioTools. This divestiture marks a strategic step for the company to streamline its portfolio. Standard BioTools operates in the life science tools industry, providing next-generation solutions and instruments for biomedical research.
Standard BioTools terminated its previously announced agreement to sell its mass cytometry business to Multiplex Bio and entered into a new definitive Share and Asset Purchase Agreement with Element Biosystems, LLC, a subsidiary of GMT Venture Partners. The company agreed to pay Multiplex Bio a $1.5 million termination fee, of which GMT Venture contributed $1.0 million on the Company’s behalf. Under the new agreement, Element will acquire the business for an aggregate purchase price of $5.5 million in cash, payable at closing subject to customary adjustments and without the obligation to provide a $10 million working capital loan required by the terminated deal. The transaction is expected to close by the end of 2026, substantially concurrently with the Company’s pending merger with Treeline Biosciences, contingent upon stockholder approval and other conditions. Standard BioTools Inc. operates in the life science tools industry, providing next-generation solutions for biomedical research.
Standard BioTools reported second quarter 2026 revenue of $20.1 million, a 7.6% decline year-over-year, driven by drops in consumables and services revenue. The company posted an operating loss of $25.4 million and a net loss from continuing operations of $21.5 million, though adjusted EBITDA improved significantly to a loss of $2.5 million from $16.1 million in the prior year period due to cost discipline and restructuring actions. Operating expenses included $14.7 million in transaction costs related to its pending merger with Treeline Biosciences. The company withdrew its full-year 2026 revenue outlook given the status of the merger, which is progressing toward a stockholder vote and anticipated closing before year-end 2026. Standard BioTools operates in the life science tools industry, providing next-generation solutions for biomedical research.
Standard BioTools Inc. filed an amended Current Report on Form 8-K to include the full Share and Asset Purchase Agreement as Exhibit 2.1, previously summarized in a filing dated July 28, 2026. The agreement outlines the acquisition by Multiplex Bio Inc. of Standard BioTools' mass cytometry business. This transaction is part of broader strategic moves involving the Treeline transaction, for which a registration statement on Form S-4 was filed on July 20, 2026. Both transactions require stockholder approval and are subject to various closing conditions. The filing serves to provide investors with the definitive contractual terms regarding the disposition of the mass cytometry business. Standard BioTools Inc. operates in the biotechnology industry, developing instruments and reagents for genomic analysis.
Standard BioTools entered into a Termination, Waiver and Release Agreement with Illumina, receiving approximately $30 million in cash to waive the 2026 earnout and terminate related royalty and license agreements. Simultaneously, the Company signed a Share and Asset Purchase Agreement to sell its mass cytometry business to Multiplex Bio for up to $10 million, consisting of a $5 million promissory note and a potential $5 million milestone payment. The transaction requires Multiplex Bio to secure a senior secured working capital loan or receive a working capital loan from Standard BioTools of up to $10 million. These strategic moves support the pending merger with Treeline Biosciences, which received early FTC clearance. Standard BioTools operates in the life science tools industry, providing next-generation solutions for biomedical research.
Standard BioTools Inc. received a notification from Nasdaq on July 22, 2026, stating the company failed to meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The deficiency occurred because the share price closed below $1.00 for 30 consecutive business days. The company has a 180-day compliance period ending January 19, 2027, to restore compliance by maintaining a minimum bid price for at least 10 consecutive business days. Trading of the common stock under the ticker LAB remains uninterrupted. Standard BioTools Inc. is a life sciences company providing tools and instruments for biological research.